Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon A Mahal

Showing results (141-150 of 214) with videos related to

Pageof 22
Sort By:
Cancer|January 12, 2019
Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?Alexander P Cole, Sean A Fletcher, Sebastian Berg, et al.
Advances in Radiation Oncology|November 4, 2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19Nicholas G Zaorsky, James B Yu, Sean M McBride, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|May 19, 2025
Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United StatesShriya K Garg, Khushi Kohli, Isha K Garg, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
The Journal of Urology|November 12, 2018
Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving HospitalsMarieke J Krimphove, Sean A Fletcher, Alexander P Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2018
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint InhibitorsLuke R G Pike, Andrew Bang, Brandon A Mahal, et al.
Urologic Oncology|May 21, 2015
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imagingVinayak Muralidhar, Kathryn T Dinh, Brandon A Mahal, et al.
JCO Oncology Practice|November 18, 2022
Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and QualityEdward Christopher Dee, Neil K Taunk, Fumiko L Chino, et al.
European Urology|December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Pageof 22

Showing results (141-150 of 214) with videos related to

Sort By:
Pageof 22
Cancer|January 12, 2019
Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?Alexander P Cole, Sean A Fletcher, Sebastian Berg, et al.
Advances in Radiation Oncology|November 4, 2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19Nicholas G Zaorsky, James B Yu, Sean M McBride, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|May 19, 2025
Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United StatesShriya K Garg, Khushi Kohli, Isha K Garg, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
The Journal of Urology|November 12, 2018
Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving HospitalsMarieke J Krimphove, Sean A Fletcher, Alexander P Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2018
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint InhibitorsLuke R G Pike, Andrew Bang, Brandon A Mahal, et al.
Urologic Oncology|May 21, 2015
Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imagingVinayak Muralidhar, Kathryn T Dinh, Brandon A Mahal, et al.
JCO Oncology Practice|November 18, 2022
Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and QualityEdward Christopher Dee, Neil K Taunk, Fumiko L Chino, et al.
European Urology|December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Pageof 22